Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 5.21% |
| CYNOSURE INC | CYNO | 4.42% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
| BLOOMIN' | BLMN | 2.93% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently, Microchip Technology Incorporated (MCHP - Analyst Report) announced that Microchip and Standard Microsystems Corporation () were granted early termination of the waiting period on May 18, 2012, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
The grant comes in connection with the merger between the two companies. On May 2, 2012, Microchip Technology signed a definitive agreement to acquire Standard Microsystems Corporation for $37.00 per share in cash for about $939 million. The net value comes to $766 million, excluding SMSC’s cash and investments on its balance sheet of approximately $173 million.
Microchip also announced that the required non-U.S. filings for pre-closing antitrust clearance applicable to the merger have been submitted. The filings were submitted in China, Korea, Germany and Turkey by the end of May and early June.
Meanwhile, the completion of the merger remains subject to antitrust clearance in these countries along with approval by the stockholders of Standard Microsystems (to be decided on July 10, 2012).
Nevertheless, Microchip expects to close the acquisition by the third quarter of 2012. Microchip expects this acquisition to be accretive to the bottom line in the first quarter after its completion. Microchip believes that SMSC’s smart mixed-signal connectivity solutions aimed at embedded applications will perfectly complement Microchip’s embedded control business. We view this acquisition a definite positive. Standard Microsystems reported net sales of $412 million in fiscal 2012, which ended in February. The acquisition is expected to broaden Microchip’s existing product portfolio with the addition of SMSC’s new products and capabilities in the automotive, industrial, computing, consumer and wireless audio markets.
We currently have a ‘Neutral’ recommendation on Microchip. Our Neutral recommendation is supported by a Zacks #3 Rank, which translates into a short-term rating of ‘Hold’.
Read the full Analyst Report on MCHP